Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

hypertension - strategy - all type of patients  


Related trials

Cardio-Sis, 2009 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ACCORD blood pressure, 2008 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

REIN-2, 2005 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

AASK, 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

Toto, 1995 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

HOT, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

MDRD, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie



See also:

  • All hypertension clinical trials
  • All clinical trials of strategy
  • All clinical trials of more intensive blood pressure lowering strategie
    		•  

    AASK study, 2002

    Treatments

    Studied treatment arterial pressure goal of 92 mm Hg or lower
    Control treatment usual mean arterial pressure goal of 102 to 107 mm Hg/pj
    Remarks 3 x 2 factorial trial: 2 mean arterial pressure goals and initial treatment with a beta-blocker, an ACE inhibitor or a dihydropyridine calcium channel blocker
    Treatments description
    Achieved systolic blood 128/141 
    Achieved diastolic blood pressure 78/85 

    Patients

    Patients African-Americans,with diastolic blood pressure higher than 94mmHg and a glomerular filtration rate between 20 and 65 ml/min per 1.73 m2
    Inclusion criteria diastolic blood pressure higher than 94mmHg; age between 18 to 70 years; glomerular filtration rate between 20 and 65 ml/min per 1.73 m2; no other identified cause of renal disease
    Exclusion criteria diastolic blod pressure of less than 95 mmHg, known history of diabetes mellitus, urinary protein to creatinine ratio of more than 2.5, accelerated or malignant hypertension within 6 months, secondary hypertension, evidence of non-BP-related causes of chronic kidney disease, serious systemic disease, clinical congestive heart failure, or specific indication for or contraindication to a study drug
    Baseline characteristics
    Number of antihypertensive drugs 3.04/2.39 

    Method and design

    Randomized effectives 540 / 554 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration (range 3-6.4y)
    Number of centre 21
    Geographic area USA


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Cardiovascular death

    15 / 540
         16 / 554
         0,96 [0,48;1,93]

    Major cardiovascular events

    51 / 540
         60 / 554
         0,87 [0,61;1,24]

    All cause death

    37 / 540
         43 / 554
         0,88 [0,58;1,35]

    non cardiovascular death

    23 / 540
         27 / 554
         0,87 [0,51;1,50]

    End stage renal disease

    81 / 540
         90 / 554
         0,92 [0,70;1,22]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Cardiovascular death 15 / 540 (2,8%) 16 / 554 (2,9%) 0,96 [0,48;1,93]   11040 
    Major cardiovascular events 51 / 540 (9,4%) 60 / 554 (10,8%) 0,87 [0,61;1,24]   11040 
    All cause death 37 / 540 (6,9%) 43 / 554 (7,8%) 0,88 [0,58;1,35]   11040 
    non cardiovascular death 23 / 540 (4,3%) 27 / 554 (4,9%) 0,87 [0,51;1,50]   11040 
    End stage renal disease 81 / 540 (15,0%) 90 / 554 (16,2%) 0,92 [0,70;1,22]   11040 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11040: Arguedas JA, Perez MI, Wright JMTreatment blood pressure targets for hypertension.Cochrane Database Syst Rev 2009;:CD004349

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Cardiovascular death 2,78% 2,89% -1,1‰
    Major cardiovascular events 9,44% 10,83% -13,9‰
    All cause death 6,85% 7,76% -9,1‰
    non cardiovascular death 4,26% 4,87% -6,1‰
    End stage renal disease 15,00% 16,25% -12,5‰


    Reference(s)

    Trials register # NA
    • Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.. JAMA 2002;288:2421-31
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend